Oncology

Novel Approaches to PARP Inhibitor Therapy for Prostate Cancer


Thursday, December 14, 2017 | 12 p.m. - 1 p.m. Add to Calendar

Houston Methodist Center for Inflammation & Epigenetics presents:

Timothy C. Thompson, PhD
Joan and Stanford Alexander Distinguished Chair for Prostate Cancer Research
Director of Prostate Cancer Basic Science Research
Professor of Genitourinary Medical Oncology
Research Division of Cancer Medicine
The University of Texas MD Anderson Cancer Center

“NOVEL APPROACHES TO PARP INHIBITOR THERAPY FOR PROSTATE CANCER”

Abstract
Androgen deprivation therapy has been the standard of care for advanced prostate cancer for decades, yet men with this condition inexorably develop resistance and progress to metastatic castration-resistant prostate cancer (mCRPC). Second generation androgen receptor signaling inhibitors like enzalutamide or poly (ADP-ribose) polymerase (PARP) inhibition by olaparib can prolong survival. However, resistance almost invariably arises as well. Enzalutamide-resistant mCRPC can be associated with neuroendocrine differentiation and neuroendocrine prostate cancer, a lethal condition. This lecture will describe efficacy and mechanistic studies using preclinical models to optimize enzalutamide and PARP inhibitor combination therapy and address the role of PARP in neuroendocrine prostate cancer, along with whether combination therapies can inhibit the development of neuroendocrine prostate cancer.

For more information, visit: events.houstonmethodist.org/timothy-thompson


Location

Houston Methodist Hospital

Dunn Tower - Rio Grande D1-059
6565 Fannin Street, Houston, TX 77030

Contact

Houston Methodist Events

17133639049